<?xml version="1.0" encoding="UTF-8"?>
<p>Pivotal clinical studies have demonstrated superiority of oral NEPA plus DEX over oral palonosetron plus DEX in preventing CINV during the acute (0–24 h), delayed (25–120 h), and overall (0–120 h) phases following both cisplatin- [
 <xref rid="mdx698-B12" ref-type="bibr">12</xref>] and anthracycline–cyclophosphamide (AC)-based chemotherapy [
 <xref rid="mdx698-B13" ref-type="bibr">13</xref>, 
 <xref rid="mdx698-B14" ref-type="bibr">14</xref>]. In addition, NEPA was shown to be efficacious over multiple cycles in patients receiving either HEC or moderately emetogenic chemotherapy (MEC) [
 <xref rid="mdx698-B15" ref-type="bibr">15</xref>].
</p>
